New drug combo aims to shrink tumors before breast cancer surgery
NCT ID NCT05069038
Summary
This study is testing whether adding a drug called palbociclib to standard hormone therapy can better shrink tumors before surgery in people with early-stage, hormone-positive breast cancer. It involves 51 participants and aims to see if this combination improves treatment response and makes surgery more feasible. The approach is for patients whose cancer may not respond well to chemotherapy before surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Unversity of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.